© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 3, 205-216,
February 2, 2000
© 2000 Oxford University Press
SPECIAL ARTICLE |
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Affiliations of authors: P. Therasse, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, European Organization for Research and Treatment of Cancer, Brussels, Belgium; S. G. Arbuck, R. S. Kaplan, L. Rubinstein, M. C. Christian, National Cancer Institute, Bethesda, MD; E. A. Eisenhauer, National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; J. Wanders, New Drug Development Office Oncology, Amsterdam, The Netherlands; S. G. Gwyther, East Surrey Healthcare National Health Service Trust, Redhill, U.K.
Correspondence to: Patrick Therasse, M.D., European Organization for Research and Treatment of Cancer Data Center, Avenue Mounier 83/11, 1200 Brussels, Belgium (e-mail: pth{at}eortc.be).
Anticancer cytotoxic agents go through a process by which their antitumor activity—on the basis of the amount of tumor shrinkage they could generate—has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
- Ignace Vergote, Gordon J. S. Rustin, Elisabeth A. Eisenhauer, Gunnar B. Kristensen, Eric Pujade-Lauraine, Mahesh K. B. Parmar, Michael Friedlander, Anders Jakobsen, and Jan B. Vermorken
J Natl Cancer Inst 2000 92: 1534-1535.[Extract] [Full Text] [PDF]
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
- Gordon J. S. Rustin, Michael Quinn, Tate Thigpen, Andreas du Bois, Eric Pujade-Lauraine, Anders Jakobsen, Elizabeth Eisenhauer, Satoru Sagae, Kathryn Greven, Ignace Vergote, Andres Cervantes, and Jan Vermorken
J Natl Cancer Inst 2004 96: 487-488.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  C. Andreetta, C. Puppin, A. Minisini, F. Valent, E. Pegolo, G. Damante, C. Di Loreto, S. Pizzolitto, M. Pandolfi, G. Fasola, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer Ann. Onc., September 2, 2008; (2008) mdn592v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Carlson, A. Miron, E. A. Jarboe, M. M. Parast, M. S. Hirsch, Y. Lee, M. G. Muto, D. Kindelberger, and C. P. Crum Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention J. Clin. Oncol., September 1, 2008; 26(25): 4160 - 4165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, M. A. Rudek, P. Kulesza, W. W. Ma, J. Wheelhouse, A. Howard, Y. Khan, M. Zhao, H. Jacene, W. A. Messersmith, et al. Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors J. Clin. Oncol., September 1, 2008; 26(25): 4172 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishida, M. Hirooka, A. Hiraoka, T. Kumagi, T. Uehara, Y. Hiasa, N. Horiike, and M. Onji Treatment of Hepatocellular Carcinoma Using Arterial Chemoembolization with Degradable Starch Microspheres and Continuous Arterial Infusion of 5-Fluorouracil Jpn. J. Clin. Oncol., September 1, 2008; 38(9): 596 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann. Onc., September 1, 2008; 19(9): 1547 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Puglisi, G. G. Cardellino, D. Crivellari, C. Di Loreto, M. D. Magri, A. M. Minisini, M. Mansutti, C. Andreetta, S. Russo, D. Lombardi, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer Ann. Onc., September 1, 2008; 19(9): 1541 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., September 1, 2008; 19(9): 1605 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. O. Smith, S. G. Downey, J. A. Klapper, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, N. P. Restifo, C. L. Levy, et al. Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines Clin. Cancer Res., September 1, 2008; 14(17): 5610 - 5618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P S MURPHY, T J McCARTHY, and A S K DZIK-JURASZ The role of clinical imaging in oncological drug development Br. J. Radiol., September 1, 2008; 81(969): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhushan and C. M Walko Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Camara, A. Carrato, et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study Ann. Onc., August 20, 2008; (2008) mdn557v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al. Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-K. Tai, M.-H. Yang, L.-W. Wang, T.-L. Tsai, P.-Y. Chu, Y.-F. Wang, J.-L. Huang, and S.-Y. Chang Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer Jpn. J. Clin. Oncol., August 11, 2008; (2008) hyn073v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Olmos, H.-T. Arkenau, J. E. Ang, I. Ledaki, G. Attard, C. P. Carden, A. H. M. Reid, R. A'Hern, P. C. Fong, N. B. Oomen, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann. Onc., August 11, 2008; (2008) mdn544v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Adam, R. J. de Haas, D. A. Wicherts, T. A. Aloia, V. Delvart, D. Azoulay, H. Bismuth, and D. Castaing Is Hepatic Resection Justified After Chemotherapy in Patients With Colorectal Liver Metastases and Lymph Node Involvement? J. Clin. Oncol., August 1, 2008; 26(22): 3672 - 3680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iwanicki-Caron, F. Di Fiore, I. Roque, E. Astruc, M. Stetiu, A. Duclos, D. Tougeron, S. Saillard, S. Thureau, J. Benichou, et al. Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer J. Clin. Oncol., August 1, 2008; 26(22): 3681 - 3686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Koeberle, P. Saletti, M. Borner, D. Gerber, D. Dietrich, C. B. Caspar, W. Mingrone, K. Beretta, F. Strasser, T. Ruhstaller, et al. Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research J. Clin. Oncol., August 1, 2008; 26(22): 3702 - 3708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Azad, E. M. Posadas, V. E. Kwitkowski, S. M. Steinberg, L. Jain, C. M. Annunziata, L. Minasian, G. Sarosy, H. L. Kotz, A. Premkumar, et al. Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity J. Clin. Oncol., August 1, 2008; 26(22): 3709 - 3714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini, M. D. Michaelson, J. E. Rosenberg, R. M. Bukowski, J. A. Sosman, W. M. Stadler, T. E. Hutson, K. Margolin, C. S. Harmon, S. E. DePrimo, et al. Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma J. Clin. Oncol., August 1, 2008; 26(22): 3743 - 3748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Dodd, E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense? J. Clin. Oncol., August 1, 2008; 26(22): 3791 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Matsubara, Y. Shimada, A. Takashima, D. Takahari, Y. Hirashima, N. T. Okita, T. E. Nakajima, K. Kato, T. Hamaguchi, Y. Yamada, et al. A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takeda, K. Masuhara, and S. Kamiura Successful Management of a Leiomyomatosis Peritonealis Disseminata With an Aromatase Inhibitor Obstet. Gynecol., August 1, 2008; 112(2): 491 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T NIWA, T YOSHIDA, T DOIUCHI, K ITO, H NAKAYAMA, K ODAGIRI, and T INOUE Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy Br. J. Radiol., August 1, 2008; 81(968): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mrozek, J. Kolesar, D. Young, J. Allen, M. Villalona-Calero, and C. L. Shapiro Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC) Ann. Onc., August 1, 2008; 19(8): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Wu, S.-G. Wu, C.-H. Yang, C.-H. Gow, Y.-L. Chang, C.-J. Yu, J.-Y. Shih, and P.-C. Yang Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response Clin. Cancer Res., August 1, 2008; 14(15): 4877 - 4882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.-F. Blanc, A. C. de Oliveira, A. Santoro, J.-L. Raoul, A. Forner, et al. Sorafenib in Advanced Hepatocellular Carcinoma N. Engl. J. Med., July 24, 2008; 359(4): 378 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells N. Engl. J. Med., July 24, 2008; 359(4): 366 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Hochster, L. L. Hart, R. K. Ramanathan, B. H. Childs, J. D. Hainsworth, A. L. Cohn, L. Wong, L. Fehrenbacher, Y. Abubakr, M. W. Saif, et al. Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study J. Clin. Oncol., July 20, 2008; 26(21): 3523 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3543 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study Ann. Onc., July 15, 2008; (2008) mdn412v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al. A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4484 - 4490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, C. S. Ng, V. Badmaev, and R. Kurzrock Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4491 - 4499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gore, M. L. Rothenberg, C. L. O'Bryant, M. K. Schultz, A. B. Sandler, D. Coffin, C. McCoy, A. Schott, C. Scholz, and S. G. Eckhardt A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas Clin. Cancer Res., July 15, 2008; 14(14): 4517 - 4525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al. Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Cohen, C. J.A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3213 - 3221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. J. van Iersel, E. J. Hoekman, H. Gelderblom, A. L. Vahrmeijer, E. L. van Persijn van Meerten, F. G. J. Tijl, H. H. Hartgrink, P. J. K. Kuppen, J. W. R. Nortier, R. A. E. M. Tollenaar, et al. Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases Ann. Surg. Oncol., July 1, 2008; 15(7): 1891 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Worden, B. Kumar, J. S. Lee, G. T. Wolf, K. G. Cordell, J. M.G. Taylor, S. G. Urba, A. Eisbruch, T. N. Teknos, D. B. Chepeha, et al. Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number J. Clin. Oncol., July 1, 2008; 26(19): 3138 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sabir, R. Schor-Bardach, C. J. Wilcox, S. Rahmanuddin, M. B. Atkins, J. B. Kruskal, S. Signoretti, V. D. Raptopoulos, and S. N. Goldberg Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy Am. J. Roentgenol., July 1, 2008; 191(1): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Borner, D. Koeberle, R. Von Moos, P. Saletti, D. Rauch, V. Hess, A. Trojan, D. Helbling, B. Pestalozzi, C. Caspar, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Ann. Onc., July 1, 2008; 19(7): 1288 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Dieras, S. Limentani, G. Romieu, M. Tubiana-Hulin, A. Lortholary, P. Kaufman, V. Girre, M. Besenval, and V. Valero Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy Ann. Onc., July 1, 2008; 19(7): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Theodore, I. Skoneczna, I. Bodrogi, M. Leahy, J. M. Kerst, L. Collette, K. Ven, S. Marreaud, R. D. T. Oliver, and for the EORTC Genito-Urinary Tract Cancer Group A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) Ann. Onc., July 1, 2008; 19(7): 1304 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al. Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Mohamed, K Yasufuku, T Nakajima, K Hiroshima, R Kubo, A Iyoda, S Yoshida, M Suzuki, Y Sekine, K Shibuya, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response Thorax, July 1, 2008; 63(7): 642 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. LoRusso, S. F. Jones, K. M. Koch, N. Arya, R. A. Fleming, J. Loftiss, L. Pandite, S. Gadgeel, B. L. Weber, and H. A. Burris III Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer J. Clin. Oncol., June 20, 2008; 26(18): 3051 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al. Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2999 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, and I. E. Smith Platinum-based chemotherapy in triple-negative breast cancer Ann. Onc., June 20, 2008; (2008) mdn395v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Asomaning, A. E. Reid, W. Zhou, R. S. Heist, R. Zhai, L. Su, E. L. Kwak, L. Blaszkowsky, A. X. Zhu, D. P. Ryan, et al. MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 4010 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Ann. Onc., June 10, 2008; (2008) mdn370v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Mantoni, A. Cavallaro, R. Sauer, W. Hohenberger, and W. G. McKenna Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2699 - 2706. [Abstract] [Full Text] [PDF]
|